Leukine sargramostim: Phase I; marketed in several cancer-related indications

Researchers published in Lancet results of dose-escalating, open-label U.S. Phase I trial in

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE